News Releases

Kallyope Announces 2026 Strategic Priorities for Migraine and Metabolism Portfolio Based on Novel Neural Circuits Platform

January 7th, 2026

Kallyope To Present at the 44th Annual J.P. Morgan Healthcare Conference

December 17th, 2025

Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine

December 8th, 2025

Kallyope Announces License Agreement with Novo Nordisk

September 10th, 2024